false
0001737953
0001737953
2024-05-16
2024-05-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): May 16, 2024
REPLIMUNE GROUP, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-38596 |
|
82-2082553 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification Number) |
500
Unicorn Park Drive
Suite 303
Woburn, MA 01801
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including
area code: (781) 222-9600
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
REPL |
|
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this
chapter). Emerging growth company ¨
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 | Results of Operations and Financial Condition. |
On May 16, 2024, Replimune
Group, Inc. (the “Company”) issued a news release announcing its financial results for the fourth quarter and year ended
March 31, 2024 and certain corporate updates. A copy of the news release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
In accordance with General
Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall
not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
REPLIMUNE GROUP, INC. |
|
|
|
Date: May 16, 2024 |
By: |
/s/ Sushil Patel |
|
|
Sushil Patel |
|
|
Chief Executive Officer |
Exhibit 99.1
Replimune Reports
Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
| · | Twelve-month
primary analysis results by independent central review from the IGNYTE clinical trial of
RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 |
| · | Recent
Type C CMC meeting with the U.S. Food and Drug Administration (FDA) supports IGNYTE Biologics
License Application (BLA) submission expected in 2H 2024 |
| · | Enrollment
of first patients in Phase 3 confirmatory trial of RP1 in advanced melanoma expected in 2H
2024 |
| · | Cash
runway to fund operations into 2H 2026 |
Woburn, MA, May 16, 2024
– Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class
of oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2024 and
provided a business update.
“We have exciting milestones in
the coming months, including sharing the investigator-assessed 12-month IGNYTE data at ASCO and then the official primary analysis by
independent central review later in the second quarter,” said Sushil Patel, Ph.D., CEO of Replimune. “Importantly, the design
of our Phase 3 confirmatory IGNYTE-3 clinical trial has been agreed with the FDA, with patient enrollment planned to initiate in the
second half of the year prior to the submission of our BLA for RP1. We also completed a successful Type C meeting with the FDA to align
on our CMC plans ahead of the intended BLA. These are all critical steps as we plan for our next phase as a commercial stage company
and, pending FDA approval, prepare to bring our first oncolytic immunotherapy to patients with advanced skin cancer.”
Corporate Updates
· | The
following abstracts, including two oral presentations, will be presented at the 2024 American
Society of Clinical Oncology (ASCO) Annual Meeting, May 31-June 4: |
| o | Abstract
#9517 (Rapid Oral Abstract Session): Efficacy and safety of RP1 combined with nivolumab in
patients with anti-PD-1 failed melanoma from the IGNYTE clinical trial. |
| o | Abstract
#9511 (Rapid Oral Abstract Session): Safety, efficacy, and biomarker results from an open-label,
multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients
with uveal melanoma. |
| o | Abstract
#TPS9604 (Poster Session): A randomized, controlled, multicenter, phase 3 study of vusolimogene
oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients
with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy
(IGNYTE-3). |
| o | Abstract
#TPS4191 (Poster Session): An open-label, multicenter study investigating RP2 oncolytic immunotherapy
in combination with second-line systemic atezolizumab combined with bevacizumab in patients
with locally advanced unresectable or metastatic hepatocellular carcinoma. |
| o | Abstract
#TPS9614 (Poster Session): Trial in progress: A phase 1/2 study of Vusolimogene oderparepvec
in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis. |
| · | Manufacturing
progress. The Company completed a successful Type C meeting with the FDA that confirmed
alignment on our Chemistry, Manufacturing and Controls (CMC) plans to support our IGNYTE
anti-PD1 failed melanoma BLA submission in the 2H 2024. |
Program Highlights & Milestones
RP1
| · | RP1
combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma |
| o | The
Company presented positive six-month follow up data by investigator assessment (N=140) from
the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial late last year. The Company
is on track to present the 12-month primary analysis by independent central review in Q2
2024. |
| o | The
Company plans to enroll its first patient in the Phase 3 confirmatory IGNYTE-3 trial prior
to submitting the RP1 BLA. The Phase 3 trial design has been agreed to with the FDA and will
be a 2-arm randomized trial with a defined list of physician’s choice treatment options
as the comparator arm in advanced melanoma patients who progressed on anti-PD1 and anti-CTLA-4
therapy or are ineligible for anti-CTLA-4 treatment. |
| · | RP1
in solid organ transplant recipients with skin cancers |
| o | The
Company presented data from the ARTACUS clinical trial of RP1 monotherapy in solid organ
transplant recipients with skin cancers at the American Association of Cancer Research (AACR)
2024 Annual Meeting in April 2024. The data included 23 evaluable patients with CSCC
(n=20) and MCC (n=3). |
| o | The
data demonstrated an overall response rate (ORR) of 34.8% (8 of 23 evaluable patients, including
5 complete responses and 3 partial responses). |
| o | RP1
monotherapy was well tolerated, and the safety profile was similar to non-immunocompromised
patients with advanced skin cancers (i.e. from the IGNYTE study). No immune-mediated adverse
events or evidence of allograft rejection were observed. |
| o | The
ARTACUS clinical trial continues to enroll patients. |
| · | RP1
in combination with Libtayo® (cemiplimab-rwlc) in CSCC |
| o | The
CERPASS trial continues as planned to assess the time-based endpoints of duration of response,
progression free survival and overall survival with greater maturity. |
RP2
| o | The
protocol for the registration-directed clinical trial of RP2 combined with nivolumab in advanced
uveal melanoma is near final following input from the FDA. |
| · | RP2
in Hepatocellular Carcinoma (HCC) |
| o | The
Phase 2 clinical trial with RP2 in anti-PD1/PD-L1 progressed HCC of RP2 combined with atezolizumab
and bevacizumab is expected to initiate in 2H 2024. |
Financial Highlights
| · | Cash
Position: As of March 31, 2024, cash, cash equivalents and short-term
investments were $420.7 million, as compared to $583.4 million as of fiscal
year March 31, 2023. The decrease was primarily related to cash utilized in operating
activities in advancing the Company’s clinical development plans. |
Based
on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of March 31,
2024 will enable the Company to fund operations into the second half of 2026.
| · | Debt:
As of March 31, 2024, the debt (net of discount) balance was $44.8 million,
as compared to $28.6 million as of March 31, 2023. The increase was primarily
related to the draw down of $15 million in December 2023, at the time of the closing
of the second amendment to the loan and security agreement with Hercules. |
| · | R&D
Expenses: Research and development expenses were $42.6 million for the
fourth quarter and $175.0 million for the fiscal year ended March 31,
2024, as compared to $37.9 million for the fourth quarter and $126.5 million for
the fiscal year ended March 31, 2023. This increase was primarily due to increased
clinical and manufacturing expenses driven by the Company’s lead programs and increased
personnel expenses. Research and development expenses included $3.2 million in
stock-based compensation expenses for the fourth quarter and $14.7 million in stock-based
compensation expenses for the fiscal year ended March 31, 2024. |
| · | S,G&A
Expenses: Selling, general and administrative expenses were $16.2 million for
the fourth quarter and $59.8 million for the fiscal year ended March 31,
2024, as compared to $15.0 million for the fourth quarter and $50.6 million for
the year ended March 31, 2023. The increase was primarily driven by personnel related
costs, including sales and marketing personnel associated with pre-launch planning and build
of the Company’s commercial infrastructure. Selling, general and administrative expenses
included $4.7 million in stock-based compensation expenses for the fourth quarter
and $19.4 million in stock-based compensation expenses for the fiscal year ended March 31,
2024. |
| · | Net
Loss: Net loss was $55.1 million for the fourth quarter and $215.8
million for the fiscal year ended March 31, 2024, as compared to a net loss
of $49.2 million for the fourth quarter and $174.3 million for the fiscal
year ended March 31, 2023. |
About RP1
RP1 (vusolimogene oderparepvec) is Replimune’s
lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic
protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation
of a systemic anti-tumor immune response.
About RP2
RP2 is based on a proprietary strain
of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF to maximize tumor killing potency,
the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response. RP2 additionally expresses an anti-CTLA-4
antibody-like molecule, as well as GALV-GP R- and GM-CSF. RP2 is intended to provide targeted and potent delivery of these proteins to
the sites of immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic-immune-based efficacy
on tumors and limiting off-target toxicity.
About Replimune
Replimune
Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development
of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended
to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a
unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of
tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates
are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed
alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Forward Looking Statements
This press release contains forward
looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, including statements regarding our expectations about our cash runway, the design and advancement of
our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates,
our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the
timing thereof, and other statements identified by words such as “could,” “expects,” “intends,” “may,”
“plans,” “potential,” “should,” “will,” “would,” or similar expressions and
the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those
contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to
generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility,
the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes
in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political
and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian
and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K
and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could
differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only
as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
Replimune Group, Inc.
Condensed Consolidated
Statements of Operations
(Amounts in thousands,
except share and per share amounts)
(Audited)
| |
Year
Ended March 31, | |
| |
2024 | | |
2023 | |
Operating
expenses: | |
| | | |
| | |
Research
and development | |
$ | 174,963 | | |
$ | 126,527 | |
Selling,
general and administrative | |
| 59,810 | | |
| 50,553 | |
Total
operating expenses | |
| 234,773 | | |
| 177,080 | |
Loss
from operations | |
| (234,773 | ) | |
| (177,080 | ) |
Other
income (expense): | |
| | | |
| | |
Research
and development incentives | |
| 1,920 | | |
| 2,914 | |
Investment
income | |
| 23,356 | | |
| 10,006 | |
Interest
expense on finance lease liability | |
| (2,163 | ) | |
| (2,197 | ) |
Interest
expense on debt obligations | |
| (4,497 | ) | |
| (1,963 | ) |
Other
income (expense) | |
| 771 | | |
| (5,676 | ) |
Total
other income (expense), net | |
| 19,387 | | |
| 3,084 | |
Loss
before income taxes | |
$ | (215,386 | ) | |
$ | (173,996 | ) |
Income
tax provision | |
| 408 | | |
| 288 | |
Net
loss | |
$ | (215,794 | ) | |
$ | (174,284 | ) |
Net
loss per common share, basic and diluted | |
$ | (3.24 | ) | |
$ | (2.99 | ) |
Weighted average
common shares outstanding, basic and | |
| | | |
| | |
diluted | |
| 66,569,894 | | |
| 58,213,010 | |
Replimune Group, Inc.
Condensed Consolidated
Balance Sheets
(Amounts In thousands,
except share and per share amounts)
| |
March 31, | | |
March 31, | |
| |
2024 | | |
2023 | |
Consolidated Balance Sheet Data: | |
| | | |
| | |
Cash, cash equivalents and short-term investments | |
$ | 420,668 | | |
$ | 583,386 | |
Working capital | |
| 393,229 | | |
| 558,778 | |
Total assets | |
| 487,722 | | |
| 646,591 | |
Total stockholders' equity | |
| 374,508 | | |
| 555,292 | |
v3.24.1.1.u2
Cover
|
May 16, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 16, 2024
|
Entity File Number |
001-38596
|
Entity Registrant Name |
REPLIMUNE GROUP, INC.
|
Entity Central Index Key |
0001737953
|
Entity Tax Identification Number |
82-2082553
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
500
Unicorn Park Drive
|
Entity Address, Address Line Two |
Suite 303
|
Entity Address, City or Town |
Woburn
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
01801
|
City Area Code |
781
|
Local Phone Number |
222-9600
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001 per share
|
Trading Symbol |
REPL
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Replimune (NASDAQ:REPL)
Historical Stock Chart
From May 2024 to Jun 2024
Replimune (NASDAQ:REPL)
Historical Stock Chart
From Jun 2023 to Jun 2024